United Therapeutics Co. (NASDAQ:UTHR) Receives $357.17 Consensus PT from Analysts

United Therapeutics Co. (NASDAQ:UTHR) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $357.17.

Several equities analysts recently weighed in on the stock. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $310.00 to $321.00 in a report on Thursday, July 11th. TD Cowen raised their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. UBS Group lifted their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st.

United Therapeutics Trading Down 1.2 %

UTHR stock opened at $368.43 on Wednesday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.03. The company has a market cap of $16.34 billion, a P/E ratio of 17.42, a PEG ratio of 1.30 and a beta of 0.57. The business has a fifty day moving average of $350.66 and a 200-day moving average of $307.90.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.24 earnings per share. As a group, equities research analysts expect that United Therapeutics will post 24.72 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares of the company’s stock, valued at approximately $569,362.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,830 shares of company stock valued at $36,010,158 in the last 90 days. 12.50% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its position in United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the period. Comerica Bank grew its position in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares during the last quarter. Tri Locum Partners LP bought a new position in shares of United Therapeutics during the second quarter worth approximately $15,959,000. Finally, QRG Capital Management Inc. increased its stake in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.